Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron

被引:79
作者
Richardson, DR
Mouralian, C
Ponka, P
Becker, E
机构
[1] Heart Res Inst, Iron Metab & Chelat Grp, Sydney, NSW 2050, Australia
[2] Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2001年 / 1536卷 / 2-3期
基金
澳大利亚研究理事会; 英国医学研究理事会;
关键词
chelator; desferrioxamine; Friedreich's ataxia; iron; iron overload disease; pyridoxal isonicotinoyl hydrazone;
D O I
10.1016/S0925-4439(01)00041-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Friedreich's ataxia (FA) is a crippling neurodegenerative disease that is due to iron (Fe) overload within the mitochondrion. One therapeutic intervention may be the development of a chelator that could remove mitochondrial Fe. We have implemented the only well characterized model of mammalian mitochondrial Fe overload to examine the Fe chelation efficacy of novel chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) class. In this model we utilize reticulocytes treated with the haem synthesis inhibitor succinylacetone which results in mitochondrial Fe-loading. Our experiments demonstrate that in contrast to desferrioxamine, several of the PCIH analogues show very high activity at mobilizing Fe-59 from Fe-59-loaded reticulocytes. Further studies on these ligands in animals are clearly warranted considering their potential to treat FA. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 40 条
[1]   THE EFFECTS OF INHIBITION OF HEME-SYNTHESIS ON THE INTRACELLULAR-LOCALIZATION OF IRON IN RAT RETICULOCYTES [J].
ADAMS, ML ;
OSTAPIUK, I ;
GRASSO, JA .
BIOCHIMICA ET BIOPHYSICA ACTA, 1989, 1012 (03) :243-253
[2]   Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin [J].
Babcock, M ;
deSilva, D ;
Oaks, R ;
DavisKaplan, S ;
Jiralerspong, S ;
Montermini, L ;
Pandolfo, M ;
Kaplan, J .
SCIENCE, 1997, 276 (5319) :1709-1712
[3]   Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone analogs [J].
Becker, E ;
Richardson, DR .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1999, 134 (05) :510-521
[4]  
BOTTOMLEY SS, 1985, J BIOL CHEM, V260, P6811
[5]   Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia [J].
Bradley, JL ;
Blake, JC ;
Chamberlain, S ;
Thomas, PK ;
Cooper, JM ;
Schapira, AHV .
HUMAN MOLECULAR GENETICS, 2000, 9 (02) :275-282
[6]  
BRITTENHAM GM, 1990, SEMIN HEMATOL, V27, P112
[7]   Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion [J].
Campuzano, V ;
Montermini, L ;
Molto, MD ;
Pianese, L ;
Cossee, M ;
Cavalcanti, F ;
Monros, E ;
Rodius, F ;
Duclos, F ;
Monticelli, A ;
Zara, F ;
Canizares, J ;
Koutnikova, H ;
Bidichandani, SI ;
Gellera, C ;
Brice, A ;
Trouillas, P ;
DeMichele, G ;
Filla, A ;
DeFrutos, R ;
Palau, F ;
Patel, PI ;
DiDonato, S ;
Mandel, JL ;
Cocozza, S ;
Koenig, M ;
Pandolfo, M .
SCIENCE, 1996, 271 (5254) :1423-1427
[8]   Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes [J].
Campuzano, V ;
Montermini, L ;
Lutz, Y ;
Cova, L ;
Hindelang, C ;
Jiralerspong, S ;
Trottier, Y ;
Kish, SJ ;
Faucheux, B ;
Trouillas, P ;
Authier, FJ ;
Durr, A ;
Mandel, JL ;
Vescovi, A ;
Pandolfo, M ;
Koenig, M .
HUMAN MOLECULAR GENETICS, 1997, 6 (11) :1771-1780
[9]   BILIARY IRON EXCRETION IN RATS FOLLOWING PYRIDOXAL ISONICOTINOYL HYDRAZONE [J].
CIKRT, M ;
PONKA, P ;
NECAS, E ;
NEUWIRT, J .
BRITISH JOURNAL OF HAEMATOLOGY, 1980, 45 (02) :275-283
[10]   SUCCINYLACETONE, A POTENT INHIBITOR OF HEME-BIOSYNTHESIS - EFFECT ON CELL-GROWTH, HEME CONTENT AND DELTA-AMINOLEVULINIC-ACID DEHYDRATASE ACTIVITY OF MALIGNANT MURINE ERYTHROLEUKEMIA-CELLS [J].
EBERT, PS ;
HESS, RA ;
FRYKHOLM, BC ;
TSCHUDY, DP .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1979, 88 (04) :1382-1390